Elevara
London, GB · Founded 2025 · 14 employees on LinkedIn · 3 known investors
Elevara Medicines is a clinical-stage biotech developing ELV001, a first-in-class once-daily oral CDK4/6 inhibitor that targets fibroblast-like synoviocytes as an add-on therapy for rheumatoid arthritis and other chronic inflammatory diseases. Its drug is designed to combine with existing DMARDs for patients who have an inadequate response to standard treatments like methotrexate and TNF inhibitors.
Founders & leadership
Elevara was founded in 2025 by Emma Tinsley.
ET
Emma TinsleyFounder & former CEO (now Non-Executive Director)
MZ
Mai-Britt ZoccaCEO
Investors · 3
Frequently asked questions
- What does Elevara do?
- Elevara Medicines is a clinical-stage biotech developing ELV001, a first-in-class once-daily oral CDK4/6 inhibitor that targets fibroblast-like synoviocytes as an add-on therapy for rheumatoid arthritis and other chronic inflammatory diseases. Its drug is designed to combine with existing DMARDs for patients who have an inadequate response to standard treatments like methotrexate and TNF inhibitors.
- Who founded Elevara?
- Elevara was founded by Emma Tinsley in 2025.
- Who are Elevara's investors?
- Elevara's investors include Monograph Capital Partners, Sofinnova Partners, Forbion.
- Where is Elevara headquartered?
- Elevara is headquartered in London, GB.